Gilead legal chief, leaves Cytokinetics after 7 months as CLO. His exit comes as the biotech awaits FDA decision on a heart ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Cytokinetics (NASDAQ:CYTK) added ~10% in the premarket on Wednesday after its rival Edgewise Therapeutics (NASDAQ:EWTX) ...

California Public Employees Retirement System trimmed its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – ...

Cytokinetics, Incorporated’s CYTK share price has surged by 13.20%, which has investors questioning if this is right time to ...

Cytokinetics is a specialty biopharmaceutical company building on its over 25-years of pioneering scientific innovation with intention to create a muscle biology franchise business focused on ...

Investment analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for Cytokinetics in a research note issued to ...

Needham analyst Serge Belanger maintained a Buy rating on Cytokinetics ( CYTK – Research Report) today and set a price target of $72.00. The company’s shares closed yesterday at $35.99. Filter, ...

Cytokinetics' lead asset, Aficamten, shows promise in treating obstructive hypertrophic cardiomyopathy (oHCM) with significant improvements in exercise capacity and fewer adverse events compared ...

Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://www.cytokinetics.com. The webcast replay will be ...

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to ...